logo BDSP

Base documentaire

Fermeture du portail BDSP le 1er juillet 2019. En savoir plus...

  1. Utilization and cost of immunotherapy for allergic asthma and rhinitis.

    Article - En anglais


    Allergic rhinitis and asthma are important sources of morbidity among adults and children.

    Although immunotherapy is sometimes used to treat these conditions, there is little information on its use, adherence, or cost in the general population.


    We sought to characterize the recipients of immunotherapy for allergic rhinitis and/or asthma with respect to their immunotherapy and utilization of health care services.


    A combination of automated and manually extracted data was used to identify HMO members with diagnoses of allergic rhinitis or asthma who were treated with immunotherapy.

    Costs associated with immunotherapy and related care were examined by linear regression.

    Proportional hazards and Kaplan-Meier plots were used to evaluate duration of therapy.


    Of the 122,196 persons with a diagnosis of asthma or rhinitis, 2,667 were also treated with immunotherapy.

    Eligibility criteria were satisfied by 603 individuals who had 28,266 encounters for immunotherapy (median 48).

    Most patients (>80%) were treated with multiple allergens ; ragweed was the most common single allergen administered.

    Thirty-three percent of patients with sufficient observation time completed the intended course of 61 immunotherapy treatments.

    Females and younger patients had shorter durations of immunotherapy.

    The most common reason for discontinuation of therapy was patient's decision (54%). (...)

    Mots-clés Pascal : Asthme, Allergie, Homme, Rhinite, Traitement, Immunothérapie, Coût, Economie santé, Observance thérapeutique, Critère décision, Prescription médicale, Exploration, Appareil respiratoire pathologie, Bronchopneumopathie obstructive, Immunopathologie, ORL pathologie, Nez pathologie

    Mots-clés Pascal anglais : Asthma, Allergy, Human, Rhinitis, Treatment, Immunotherapy, Costs, Health economy, Treatment compliance, Decision criterion, Medical prescription, Exploration, Respiratory disease, Obstructive pulmonary disease, Immunopathology, ENT disease, Nose disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0259789

    Code Inist : 002B11B. Création : 16/11/1999.

Fermeture du portail BDSP le 1er juillet 2019

Nous avons le regret de vous informer de la fermeture du portail BDSP le 1er juillet 2019. Du 1er janvier au 30 juin 2019, le site et ses services resteront accessibles mais ne seront plus alimentés, ni mis à jour. En savoir plus...